Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma-Reference-Cited by-同舟云学术

Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma

Published:2019 Issue:9 Volume:66 Page:787-792
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Koizumi Yohei¹,Hirooka Masashi¹,Hiraoka Atsushi²,Ochi Hironori³,Tanaka Takaaki¹,Yukimoto Atsushi¹,Imai Yuusuke¹,Watanabe Takao¹,Yoshida Osamu¹,Miyake Teruki¹,Matsuura Bunzo¹,Michitaka Kojiro²,Joko Kouji³,Abe Masanori¹,Hiasa Yoichi¹

Affiliation:

1. Departments of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan

2. Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan

3. Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/66/9/66_EJ19-0140/_pdf

Reference24 articles.

1. 1 Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, et al. (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122: 664–671.

2. 2 Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, et al. (2008) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14: 5459–5465.

3. 3 Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, et al. (2014) Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014: 638747.

4. 4 Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, et al. (2014) Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 6: 18.

5. 5 Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, et al. (2017) Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 52: 512–519.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperthyroidism Due to Functioning Metastatic Bone Lesions of Follicular Thyroid Carcinoma Treated With Lenvatinib;JCEM Case Reports;2024-06-27

2. Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study;Cancer Immunology, Immunotherapy;2024-06-04

3. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab;Targeted Oncology;2024-04-30

4. CHOP regulated by METTL14-m6A affects cell cycle arrest and regorafenib sensitivity in HCC cells;BMC Cancer;2024-04-25

5. Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC);CPT: Pharmacometrics & Systems Pharmacology;2024-03-26